Ms. Helen Ljungdahl Round joins Acarix Inc. as the president of the company.
FREMONT, CA: “We are delighted to have recruited Helen to lead our new US operations in this intense and exciting phase for Acarix. Helen has a wealth of experience in global sales and marketing in health technology and the pharmaceutical sector. Her background and experience provide us with the right leadership to successfully drive sales of CADScor®System and establish Acarix in the North American market,” states Per Persson, CEO of Acarix. Acarix hires that Ms. Helen Ljungdahl Round as the president of the company’s newly founded US subsidiary, Acarix Inc. Helen will take her post in September 2021 and be responsible for the organization’s development in the United States. She will join the Executive Management Group of Acarix AB.
Ms. Helen Ljungdahl Round has over 25 years of experience in the pharmaceutical sector, having held executive and worldwide positions at Merck & Co, Inc (MSD) and as Senior Vice President Global Marketing & Business Development at GN Hearing. Her most recent post was as CEO of Amnicell, a New York City-based biotech start-up. Helen has spent most of her professional career in the United States, where she has worked for American firms and served on directors and advisory boards. She is renowned as an accomplished commercial leader who develops high-performing teams and organizations to deliver profitable and sustainable business results.
Ms. Helen Ljungdahl Round says, “Coronary artery disease affects 18 million adults and causes more than 365,000 deaths annually in the USA. The CADScor®System holds significant future potential in the rapid assessment and rule-out of coronary artery disease. I am looking forward to bringing CADScor®System to the US market and contributing to the health and wellness of patients with heart disease.”
Acarix is a market leader in artificial intelligence-driven diagnostics for the immediate exclusion of coronary artery disease. The US Food and Drug Administration (FDA) has received Acarix De Novo clearance for its CADScor®System, a simple-to-use, quick, and non-invasive test that may be used in both in-patient and out-patient settings. It has the potential to play a significant role in ensuring that individuals with stable coronary artery disease be evaluated and ruled out promptly and efficiently.